Literature DB >> 12865379

Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome.

Thomas W K Lew1, Tong-Kiat Kwek, Dessmon Tai, Arul Earnest, Shi Loo, Kulgit Singh, Kim Meng Kwan, Yeow Chan, Chik Foo Yim, Siam Lee Bek, Ai Ching Kor, Wee See Yap, Y Rubuen Chelliah, Yeow Choy Lai, Soon-Keng Goh.   

Abstract

CONTEXT: Severe acute respiratory syndrome (SARS) is an emerging infectious disease with a 25% incidence of progression to acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and mortality exceeding 10%.
OBJECTIVE: To describe the clinical spectrum and outcomes of ALI/ARDS in patients with SARS-related critical illness. DESIGN, SETTING, AND PATIENTS: Retrospective case series of adult patients with probable SARS admitted to the intensive care unit (ICU) of a hospital in Singapore between March 6 and June 6, 2003. MAIN OUTCOME MEASURES: The primary outcome measure was 28-day mortality after symptom onset.
RESULTS: Of 199 patients hospitalized with SARS, 46 (23%) were admitted to the ICU, including 45 who fulfilled criteria for ALI/ARDS. Mortality at 28 days for the entire cohort was 20 (10.1%) of 199 and for ICU patients was 17 (37%) of 46. Intensive care unit mortality at 13 weeks was 24 (52.2%) of 46. Nineteen of 24 ICU deaths occurred late (> or =7 days after ICU admission) and were attributed to complications related to severe ARDS, multiorgan failure, thromboembolic complications, or septicemic shock. ARDS was characterized by ease of derecruitment of alveoli and paucity of airway secretion, bronchospasm, or dynamic hyperinflation. Lower Acute Physiology and Chronic Health Evaluation II scores and higher baseline ratios of PaO2 to fraction of inspired oxygen were associated with earlier recovery.
CONCLUSIONS: Critically ill patients with SARS and ALI/ARDS had characteristic clinical findings, high rates of complications; and high mortality. These findings may provide useful information for optimizing supportive care for SARS-related critical illness.

Entities:  

Mesh:

Year:  2003        PMID: 12865379     DOI: 10.1001/jama.290.3.374

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  182 in total

1.  Use of drotrecogin alfa (activated) in a severe acute respiratory syndrome patient with severe sepsis.

Authors:  Donna McRitchie; Warda Farooq; Harold N Fisher
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-05       Impact factor: 2.471

2.  Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study.

Authors:  Yasushi Matsuzawa; Hisao Ogawa; Kazuo Kimura; Masaaki Konishi; Jin Kirigaya; Kazuki Fukui; Kengo Tsukahara; Hiroyuki Shimizu; Keisuke Iwabuchi; Yu Yamada; Kenichiro Saka; Ichiro Takeuchi; Toshio Hirano; Kouichi Tamura
Journal:  Hypertens Res       Date:  2020-08-21       Impact factor: 3.872

3.  Pandemic influenza: implications for preparation and delivery of critical care services.

Authors:  Mary-Elise Manuell; Mary Dawn T Co; Richard T Ellison
Journal:  J Intensive Care Med       Date:  2011-01-10       Impact factor: 3.510

4.  Critical role of IL-17RA in immunopathology of influenza infection.

Authors:  Christopher R Crowe; Kong Chen; Derek A Pociask; John F Alcorn; Cameron Krivich; Richard I Enelow; Ted M Ross; Joseph L Witztum; Jay K Kolls
Journal:  J Immunol       Date:  2009-09-25       Impact factor: 5.422

5.  Comparative study of synonymous codon usage variations between the nucleocapsid and spike genes of coronavirus, and C-type lectin domain genes of human and mouse.

Authors:  Insung Ahn; Byeong-Jin Jeong; Hyeon Seok Son
Journal:  Exp Mol Med       Date:  2009-10-31       Impact factor: 8.718

6.  pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN.

Authors:  Zhi-Yong Yang; Yue Huang; Lakshmanan Ganesh; Kwanyee Leung; Wing-Pui Kong; Owen Schwartz; Kanta Subbarao; Gary J Nabel
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

7.  T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS.

Authors:  Yue-Dan Wang; Wan-Yee Fion Sin; Guo-Bing Xu; Huang-Hao Yang; Tin-yau Wong; Xue-Wen Pang; Xiao-Yan He; Hua-Gang Zhang; Joice Na Lee Ng; Chak-Sum Samuel Cheng; Jing Yu; Li Meng; Rui-Feng Yang; Sik-To Lai; Zhi-Hong Guo; Yong Xie; Wei-Feng Chen; Huang-Hua Yang
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  Pregnancy and H1N1 infection.

Authors:  Lin Lin Su; Jerry Chan; Yap Seng Chong; Mahesh Choolani; Arijit Biswas; E L Yong
Journal:  Lancet       Date:  2009-10-24       Impact factor: 79.321

9.  Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice.

Authors:  Kanta Subbarao; Josephine McAuliffe; Leatrice Vogel; Gary Fahle; Steven Fischer; Kathleen Tatti; Michelle Packard; Wun-Ju Shieh; Sherif Zaki; Brian Murphy
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome.

Authors:  Mark J Cameron; Longsi Ran; Luoling Xu; Ali Danesh; Jesus F Bermejo-Martin; Cheryl M Cameron; Matthew P Muller; Wayne L Gold; Susan E Richardson; Susan M Poutanen; Barbara M Willey; Mark E DeVries; Yuan Fang; Charit Seneviratne; Steven E Bosinger; Desmond Persad; Peter Wilkinson; Larry D Greller; Roland Somogyi; Atul Humar; Shaf Keshavjee; Marie Louie; Mark B Loeb; James Brunton; Allison J McGeer; David J Kelvin
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.